All articles by Swagath Bandhakavi
Swagath Bandhakavi
AbbVie’s Elahere demonstrates extended survival in Phase 3 MIRASOL trial
Elahere outperformed investigator’s choice chemotherapy, with patients experiencing a median progression-free survival of 5.59 months compared to 3.98 months with chemotherapy
Mallinckrodt and Endo to merge in $6.7bn stock and cash deal
The merger will unite pharmaceutical brands across various therapeutic areas, including XIAFLEX, Acthar Gel, Terlivaz, SUPPRELIN LA, and AVEED
ViiV Healthcare’s N6LS shows promise in long-acting HIV treatment
The Phase IIb EMBRACE study found that N6LS, when given every four months with long-acting cabotegravir, successfully maintained viral suppression in adults with HIV who were already stable on treatment
Arvinas and Pfizer’s vepdegestrant meets primary endpoint in VERITAC-2 trial
The trial’s primary endpoint was reached as vepdegestrant demonstrated a statistically significant improvement in PFS in the ESR1m population when compared to fulvestrant
Arrowhead Pharmaceuticals reports positive results in ARO-C3 study for IgAN
The early-stage trial revealed an 89% reduction in C3 levels, underscoring the potential of the drug candidate in targeting protein production for treating complement-mediated disorders
EC authorises Bristol Myers Squibb’s Opdivo, Yervoy combo for advanced liver cancer
The approval has been driven by the findings from the CheckMate -9DW trial, which showed significant improvements in OS for patients subjected to the Opdivo-Yervoy combination
scPharmaceuticals gains FDA nod to extend FUROSCIX indication to CKD edema
Furoscix, formulated as an 80 mg/10 mL furosemide injection for subcutaneous use, has received clearance for the management of edema
CordenPharma announces €500m facility in Switzerland to boost peptide manufacturing
This initiative forms part of the Swiss CDMO’s wider plan to enhance its peptide platform, aiming for sales surpassing €1bn by 2028
WuXi Biologics introduces EffiX to enhance recombinant protein and DNA production
The new technology employs an E. coli expression system to enhance the yield and stability in the production of recombinant proteins and plasmid DNA
Rusfertide hits primary endpoint in Phase 3 VERIFY trial for polycythemia vera
The late-stage trial showed a notably higher percentage of clinical responders in patients treated with rusfertide compared to those receiving a placebo